JP2024514112A5 - - Google Patents

Info

Publication number
JP2024514112A5
JP2024514112A5 JP2023561181A JP2023561181A JP2024514112A5 JP 2024514112 A5 JP2024514112 A5 JP 2024514112A5 JP 2023561181 A JP2023561181 A JP 2023561181A JP 2023561181 A JP2023561181 A JP 2023561181A JP 2024514112 A5 JP2024514112 A5 JP 2024514112A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
pharmaceutically acceptable
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023496 external-priority patent/WO2022216719A1/en
Publication of JP2024514112A publication Critical patent/JP2024514112A/ja
Publication of JP2024514112A5 publication Critical patent/JP2024514112A5/ja
Pending legal-status Critical Current

Links

JP2023561181A 2021-04-06 2022-04-05 ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 Pending JP2024514112A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171461P 2021-04-06 2021-04-06
US63/171,461 2021-04-06
PCT/US2022/023496 WO2022216719A1 (en) 2021-04-06 2022-04-05 Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Publications (2)

Publication Number Publication Date
JP2024514112A JP2024514112A (ja) 2024-03-28
JP2024514112A5 true JP2024514112A5 (https=) 2025-04-09

Family

ID=81387274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561181A Pending JP2024514112A (ja) 2021-04-06 2022-04-05 ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法

Country Status (7)

Country Link
US (1) US20240366609A1 (https=)
EP (1) EP4319749A1 (https=)
JP (1) JP2024514112A (https=)
KR (1) KR20230165795A (https=)
CN (1) CN117561062A (https=)
TW (1) TW202304438A (https=)
WO (1) WO2022216719A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119606963B (zh) * 2025-02-13 2025-07-18 中国农业大学 一种有效清除衰老肠细胞的药物及其在治疗肠道炎症病症中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
BR112014015720B1 (pt) 2011-12-30 2020-03-17 Hanmi Pharm. Co., Ltd. Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
KR102811888B1 (ko) * 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
CN114269376A (zh) * 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法

Similar Documents

Publication Publication Date Title
Kawashita et al. Oral management strategies for radiotherapy of head and neck cancer
JP2022009090A5 (https=)
JP2023174661A5 (https=)
JP2019503365A5 (https=)
JP2014526503A5 (https=)
JP2022533578A5 (https=)
JP2018507243A5 (https=)
JP2023175694A5 (https=)
JP2025020117A5 (https=)
JP2021152008A5 (https=)
JP2012522837A5 (https=)
JP2021509395A5 (https=)
McCann et al. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CN109985237A (zh) 一种治疗结直肠癌的药物组合物及其应用
JP2022523045A5 (https=)
JP2023545372A5 (https=)
JP2023521036A5 (https=)
JP2024514112A5 (https=)
JP2016505050A5 (https=)
JP2023531675A5 (https=)
JP2023524359A5 (https=)
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022058873A5 (https=)
JP2024535880A5 (https=)